United Therapeutics' stock plummeted 7.19% during intraday trading on Thursday, as the company reported fourth-quarter revenue for its Tyvaso franchise and Tyvaso dry powder inhaler that fell short of market expectations.

Despite overall revenue growth to $790.2 million from $735.9 million a year earlier and earnings per share increasing to $7.70 from $6.19, the miss in key product lines weighed on investor sentiment. The company also announced development of a soft-mist inhaler for Tyvaso, which could improve market share upon potential launch in 2027, but this longer-term positive was overshadowed by the immediate revenue disappointment.

Analysts from RBC Capital Markets noted the revenue miss but raised their price target on the stock to $643 from $587, maintaining an Outperform rating, citing the potential of the new inhaler technology.